Evotec AG and Boehringer Ingelheim have extended their research collabration for four more years. The collaboration was initiated in August 2004 and has been extended on two previous occasions. Based on the success to date in the areas of CNS, inflammation, cardiometabolic and respiratory diseases, the companies have elected to expand the scope of the collaboration to also include oncology targets. Through the term of the extension, Evotec will receive research funding of $22 million, as well as...